ABSTRACT
Objective To investigate the efficacy and toxicity of etoposide combined with prednisone (EtoP regimen) for elderly patients with unspecific peripheral T-cell lymphoma (PTCL-U) compared with the CHOP regimen.Methods 23 elderly PTCL-U patients were randomly assigned to EtoP group (n =12) or CHOP group (n =11).The curative effects and the adverse reactions were analyzed and compared between the two groups by Log-rank test and x2 test.Results The overall response (OR) rate was 66.67 ％ (8/12) in EtoP group and 63.64 ％ (7/11) in CHOP group.There was no statistically significant difference between the two groups(x2 =0.023,P =0.879).The progression-free survival (PFS) was 7.55 months in EtoP group and 4.38 months in CHOP group,statistically significant difference were observed between the two groups (x2 =23.000,P =0.011).The overall survival (OS) was 15.02 months in EtoP group and 12.26 months in CHOP group,no statistically significant difference was observed between the two groups (x 2 =14.985,P =0.597).The main side effects were bone marrow depression and digestive tract toxicity,no hematology toxicity and digestive tract toxicity of grade Ⅲ-Ⅳ occurred in EtoP group.Of those in CHOP group were 36.36 ％ and 27.27 ％.Conclusion For elderly PTCL-U patients,EtoP regimen is an effective and well tolerated therapeutic schedule.
ABSTRACT
Objective To observe the influence of T cell subsets and natural killer cell ofcytokine induced killer (CIK) therapy for partial advanced non-small cell lung cancer patients.Methods Sixty-one patients with partial advanced non-small cell lung cancer were randomly divided into treatment group and control group by sortition method.In treatment group,31 patients received three dimensional conformal radiation therapy and chemotherapy,then received CIK treatment.In control group,30 patients received three dimensional conformal radiation therapy and chemotherapy.Results In treatment group,CD3+,CD4+,CD4+/CD8+ and CD16+ CD56+ after treatment were significantly higher than before treatment (0.7125 ± 0.0154 vs.0.6374 ± 0.0325,0.3921 ± 0.0461 vs.0.3217 ± 0.0287,0.0178 ± 0.0179 vs.0.0102 ± 0.0093,0.1855 ± 0.0321 vs.0.1224 ± 0.0177),CD8+ after treatment was significantly lower than before treatment (0.2209 ± 0.0257 vs.0.3147 ± 0.0307),there was significant difference (P ＜ 0.05).In control group,there were no significant difference in CD3+,CD4+,CD8+,CD4+/CD8+ and CD16+ CD56+ between after treatment and before treatment (0.6218 ± 0.0040 vs.0.6325 ± 0.0114,0.3311 ± 0.0278 vs.0.3347 ± 0.0209,0.3265 ± 0.0257 vs.0.3316 ± 0.0178,0.0101 ± 0.0108 vs.0.0101 ± 0.0117,0.1327 ± 0.0298 vs.0.1479 ± 0.0354,P ＞ 0.05).The side effects in the treatment group and control group showed no significant difference (P ＞0.05).Conclusion CIK therapy can improve immune function in patients with partial advanced non-small cell lung cancer.
ABSTRACT
Objective To investigate the apoptosis-inducing effect of L-gossypol on human nasopharyngesl carcinoma cell line CNE2 and its possible mechanism.Methods The effect of L-gossypol on proliferation of CNE2 cells was estimated by MTT assay.Flow cytometry was used to analyz cell apoptosis induced by(-)-gossypol and the expression of Bcl-2 、Bax proteins.Caspase-3 activity was determined by caspase-3 colorimetric assay kit.Results Lgossypol was able to inhibit the proliferation of CNE2 cells in a dose-dependent and time-dependent fashion at concentrations more than 10 μmoL/L.L-gossypol regulated cell cycle and GO/G1 arrest could be observed in CNE2 cells.In the process of apoptosis,the expression of Bcl-2 was down-regulated and Bax was up-regulated,caspase-3 activity was in peak at 24h.Conclusion L-gossypol could induce apoptosis in nasopharyngeal carcinoma cell line CNE2 in vitro,which may be associated with down-regulation of Bcl-2,up-regulation of Bax genes expression and caspase-3 activation.
ABSTRACT
OBJECTIVE:To study the pharmacokinetics of a single dose of intramuscularly injected ziprasidone mesylate in healthy volunteers.METHODS:A total of10healthy volunteers were received intramuscularly single dose of ziprasidone me-sylate20mg,venous blood samples were taken at different time after intramuscular injection,the concentrations of ziprasidone in serum were determined by HPLC,and the pharmacokinetic parameters were calculated with3p97program.RESULTS:The concentration-time curves of ziprasidone fitted to two-compartment model.The pharmacokinetic parameters were stated as follows,C max was(866.32?482.88)ng/ml;t max was(0.57?0.23)h,t 1/2ke was(2.17?1.04)h,CL was(17.0?9.00)ml/h,AUC 0～12 was(1467.94?644.80)(ng?h)/ml and ACU 0～∝ was(1603.48?722.47)(ng?h)/ml.CONCLUSIONS:The pharmacoki-netics parameters in10healthy volunteers after intramuscular injection of20mg ziprasidone mesylate are in line with that re-ported in the literature.